Iron imbalance in cancer: Intersection of deficiency and overload

Tulika Basak1 | Rupinder Kaur Kanwar1,2

1Institute for Innovation in Mental and Physical Health and Clinical Translation (IMPACT), School of Medicine, Faculty of Health, Deakin University, Geelong, Victoria, Australia
2Department of Translational Medicine Centre, All India Institute of Medical Sciences (AIIMS) Bhopal, Bhopal, India

Correspondence
Dr Rupinder Kaur Kanwar, Department of Translational Medicine Centre, All India Institute of Medical Sciences (AIIMS) Bhopal, Saket Nagar, Bhopal-462020, Madhya Pradesh (MP), India.
Email: rupinder.tmc@aiimsbhopal.edu.in

Funding information
The authors acknowledge the funding support of Deakin University for Postgraduate Research Scholarship (DUPRS) awarded to Miss Tulika Basak. And also the authors gratefully acknowledge the funding support by Mr Geoff Garlinge, and Australia's Own Pty Ltd. The Entrance, NSW Australia, towards open access article publication charges.

Abstract
Iron, an essential trace element, plays a complex role in tumour biology. While iron causes cancer clearance through toxic free radical generation, iron-induced free radical flux also acts as a cancer promoter. These fates majorly guided through cellular response towards pro-oxidant and antioxidant settings in a tumour microenvironment, designate iron-induced oxidative stress as a common yet paradoxical factor in pro-tumorigenesis as well as anti-tumorigenesis, posing a challenge to laying down iron thresholds favouring tumour clearance. Additionally, complexity of iron’s association with carcinogenesis has been extended to iron-induced ROS’s involvement in states of both iron deficiency and overload, conditions identified as comparable, inevitable and significant coexisting contributors as well as outcomes in chronic infections and tumorigenesis. Besides, iron overload may also develop as an unwanted outcome in certain cancer patients, as a result of symptomatic anaemia treatment owed to irrational iron-restoration therapies without a prior knowledge of body’s iron status with both conditions synergistically acting towards tumour aggravation. The co-play of iron deficiency and overload along with iron’s pro-tumour and antitumour roles with intersecting mechanisms, thus presents an unpredictable regulatory response loop in a state of malignancy. The relevance of iron’s thresholds beyond which it proves to be beneficial against tumorigenesis hence becomes questionable. These factors pose a challenge, over establishing if iron chelation or iron flooding acts as a better approach towards antitumour therapies. This review presents a critical picture of multiple contrasting features of iron’s behaviour in cancer, leading towards two conditions lying at opposite ends of a spectrum: iron deficiency and overload in chronic disease conditions including cancer, hence, validating the critical significance of diagnosis of patients’ iron status prior to opting for subsequent therapies.

KEYWORDS
anaemia, cancer, inflammation, iron, iron deficiency, iron overload, reactive oxygen species (ROS)
1 | INTRODUCTION

Iron, an essential trace element, participates as a cofactor in several enzymes required in biochemical functions in human physiology. Its behaviour is attributed to its potential to readily donate and accept electrons, thus inter-switching between insoluble ferric (Fe\(^{3+}\)) and soluble ferrous (Fe\(^{2+}\)) forms. However, this redox ability makes iron a paradoxical element, due to its potential toxicity towards cells under imbalanced conditions, despite being a key factor in normal anatomical functioning.  

Iron imbalance in the body occurs when regulatory processes for intracellular iron maintenance function abnormally, or iron intake exceeds the required physiological range. Both conditions of iron deficiency and overload may be detrimental to optimal body functioning, consequently catalysing cancer incidence, recurrence and chronic infections. Additionally, with iron chelation as an approach towards anticancer therapy, iron-driven oxidative injury presents a contrasting view on the role of iron in anticancer applications. Besides, irrational iron administration or chronic red blood cell (RBC) transfusion therapies clinically prescribed for treatment of iron deficient or chemotherapy-induced anaemia (CIA), may lead to unwanted risks of iron overload, further aggravating the disease. One such example is cancer-driven chronic anaemia clinically indicated by deficient available or functional iron that might render iron administration counterproductive, thus intensifying risks of malignancy. In this review, we, therefore, discuss a possible link on the contradictory role of iron deficiency and overload in chronic conditions including cancer, signifying the diagnosis of iron status in cancer patients prior to opting for iron-restoration strategies.

2 | IRON-REGULATORY MECHANISM

A healthy human body contains approximately 3–4 grams of iron, majorly intracellularly available, with an average of 64% circulating as haemoglobin (Hb) in erythrocytes, or as stored as ferritin reserves in hepatocytes, along with about 21% contained in macrophages, and 14% in myoglobin and iron-containing enzymes in various cell types. Blood plasma, on the other hand, contains minor amounts of iron in the range of a few milligrams with nearly all of it bound to iron-binding plasma glycoprotein, transferrin (Tf), with its iron-binding sites approximately 20%–40% saturated with ferric (Fe\(^{3+}\)) atoms. Under optimal health conditions, dietary or cellular iron in Fe\(^{3+}\) form complexed with Tf binds to the cell surface transferrin receptor (TfR), further internalised through endocytosis via receptor-mediated delivery. Fe\(^{3+}\) is then released from the complex due to the acidic environment of the early endosome, in order to undergo reduction to ferrous form by an enterocytic ferrireductase, duodenal cytochrome B (DcytB). However, with DcytB reported to exhibit low expression in erythroid precursor cells, an NADPH dependent, membrane bound erythroid protein, the six-transmembrane epithelial antigen of prostate 3 (STEAP3) was identified as yet another ferrireductase responsible for endosomal iron reduction. Post reduction, Fe\(^{2+}\) is delivered to the cytoplasm by duodenal enterocytes via divalent metal transporter 1 (DMT1), known to be selective for Fe\(^{2+}\), post which Fe\(^{2+}\) is released into circulation via ferroportin (FPN), the major iron exporter, rendering it available for oxidation by a transmembrane ferroxidase, hephaestin. Figure 1 schematically represents the general mechanism of cellular iron metabolism in a healthy human body. Resulting ferric ions complexed with Tf are further delivered to bone marrow which get transported to peripheral tissues through receptor-mediated delivery, for essential functions. Excessive iron is stored as ferritin reserves in macrophages, until required for erythropoiesis. Erythropoietin being the RBC regulator, requires the release of stored iron via FPN for Hb synthesis. Hepcidin regulation is partially driven by hepcidin, a hepatic peptide identified as the systemic iron regulator. Hepcidin-FPN interplay in liaison with, hephaestin, therefore, controls intestinal iron absorption, plasma iron concentration and its circulatory release throughout the body.

The iron-regulatory mechanism is however disrupted in cancer and cancer-associated chronic inflammation. Tumour microenvironment is actively regulated and modulated by inflammatory cells through a single or a concerted effect of several cytokines including interleukins, oncostatin and leptins. This induces hepcidin release, thus disrupting the FPN/hepcidin channel, and inhibiting macrophageal iron export, leading to an ‘iron-blockage’. Resulting reduced serum iron and increased ferritin stores lead to a state of ‘functional iron deficiency’ (FID) in cancer patients, one of the predominant mechanisms in cancer-associated iron deficit. FID as a response to cancer is critical, since it is noteworthy that while cancer patients possess adequate or increased iron stores with elevated hepcidin, this iron is inaccessible for erythropoiesis. FID prevalence increases with cancer stages and is correlated to treatment-associated underperformance in cancer patients. Alternately, iron deficiency may also be absolute abbreviated as AID, marked by a complete depletion of iron reserves and iron unavailability for RBC synthesis. Differences between FID and AID have been illustrated in Figure 2. Taken together, the common event in both AID and FID is a significant reduction or unavailability of iron for erythropoiesis, thereby resulting
Basak and Kanwar

interestingly, while anaemia of chronic diseases (ACD) indicates a state of iron deficiency, it has been reflected to associate with the phenotypic expression of hereditary hemochromatosis (HH), an iron overload disorder.\(^{16}\) Unsurprisingly, inflammation-induced expression of HFE, a distinguished contributor in HH has been previously hypothesised to associate with ACD acting through iron blockage in reticuloendothelial cells via inhibition of FPN-mediated iron export, therefore, implying a possible link between states of iron deficiency and overload.\(^{17,18}\)

in clinical anaemia in chronic inflammations, including cancer.

Figure 1: A schematic representation of iron-regulatory axis—from intestinal lumen to circulation. Reduced iron is absorbed by duodenal enterocytes via divalent metal transporter 1 (DMT1) or heme carrier protein-1 (HCP-1), then transported to blood vessels via ferroportin (FPN), the major iron exporter. Hepcidin-FPN interplay in liaison with a transmembrane ferroxidase, hephaestin controls intestinal iron absorption, plasma iron concentration and its circulatory release throughout the body. Ferric ion (Fe\(^{3+}\)) complexed with transferrin (Tf) is further delivered to bone marrow which gets transported to peripheral tissues through receptor-mediated delivery, for essential functions. Excessive iron is stored as ferritin reserves until required for erythropoiesis. Abbreviation: DcytB = Duodenal cytochrome B.

Figure 2: A diagrammatic representation of states of absolute and functional iron deficiencies (AID and FID, respectively) as compared to healthy iron status. FID and AID are characterised by significant reduction or unavailability of iron for erythropoiesis, thereby resulting in clinical anaemia in chronic inflammations, including cancer. FID is a condition of iron deficiency marked by adequate or increased iron stores with elevated hepcidin, while this iron is inaccessible for erythropoiesis. AID, on the other hand, indicates a complete depletion of iron reserves and iron unavailability for red blood cell (RBC) synthesis.
Mutations in iron-regulatory genes, including \textit{HFE} result in functional hepcidin deficiency and duodenal FPN overexpression, thus causing iron over-absorption in the gastrointestinal tract, one of the suspected contributors in malignancy, particularly hepatic and colorectal cancers.\textsuperscript{19} Resulting increased intestinal iron transfer to plasma saturates Tf, releasing free iron known as ‘non-transferrin bound iron’ (NTBI).\textsuperscript{20} NTBI is potent reactive oxygen species (ROS) generator resulting in tissue injury and lipid peroxidation, eventually inducing DNA damage and therefore, are drivers for cancer progression.\textsuperscript{21} This ability is exploited by hepatocytes, predominantly parenchymal cells, being sites for FPN expression and having limited iron export ability, resulting in excessive hepatocyte iron flush due to hepcidin deficiency.\textsuperscript{22} Paradoxically, low hepcidin production as a result of iron deficiency has also been associated with risks of chronic liver complications and hepatic cancer.\textsuperscript{23,24}

The above-mentioned factors cumulatively indicate a possible association between iron deficiency and overload in cancer that might be owed to uncondoned iron-restoration therapies, an underappreciated topic over the years, and therefore, needs to be individually discussed.

\section{IRON IMBALANCE AND ROS LINK IN CANCER}

A major factor behind the iron-cancer link is iron’s ability to undergo redox reactions, the source of hypoxia-inducing toxic free radicals/ROS, responsible for cellular oxidative stress.\textsuperscript{25} One of the predominant mechanisms governing iron’s association with cancer initiates as a protective mechanism of the cell’s intrinsic property to eliminate superoxides (O$_2^-$), identified as the primary ROS molecule generated from essential cellular metabolic processes. However, given the proactive metabolic state of tumour cells, overly accumulated ROS along with overall enhanced oxidative stress promote accumulation of endogenous free radical, hydrogen peroxide (H$_2$O$_2$), a step catalysed by an antioxidant, superoxide dismutase which in presence of excess Fe$^{2+}$ generates a hydroxyl radical (OH$^-$) flux through a process called Fenton reaction.\textsuperscript{26,27} These free radicals, in turn, have the ability to drive lipid peroxidation and loss of membrane integrity, an outcome identified as a common event favouring both pro-tumorigenesis and anti-tumorigenesis, the fate being majorly dependent on comparative ROS levels against cellular antioxidant defence (AOD).\textsuperscript{26,27} Given this mode of action as schematically represented in Figure 3, while iron-generated free radicals may stimulate anti-tumorigenic signalling and drive oxidative stress-promoted tumour clearance, cancer cells often have the ability to adapt to the hypoxic environment, triggering cellular transformation pathways facilitating their survival and proliferation.\textsuperscript{25,28}

ROS’s anti-tumorigenic effect acting through iron-induced accumulation of lethal amounts of lipid peroxides as a result of Fenton’s reaction can be attributed to ferroptosis, an iron-dependent non-apoptotic cell death also identified as an outcome of unrestricted oxidative stress via erastin-induced inactivation of an antioxidant enzyme, glutathione peroxidase 4 (GPX4).\textsuperscript{29} However, while ferroptosis appears to be a favourable outcome in terms of cancer treatment, it has the ability to induce significant damage to healthy cells while promoting degenerative pathological defects, including carcinogenesis, owing to the declining cellular ability to repair lipid peroxide damages.\textsuperscript{30,31} Furthermore, ferroptosis in cancer cells have been reported to induce prostaglandin E2 release thus affecting its role in immunosuppression, in turn driving chemotherapy resistance and tumour cell proliferation.\textsuperscript{32} Besides, the interplay of the intrinsic antioxidant machinery of cancer cells and administration of iron chelators as an initial part of chemotherapy may synergistically act to hinder or neutralise the positive impact or induction of ferroptosis.\textsuperscript{30} On the other hand, with antioxidant defence used as a common death evading strategy by cancer cells to regulate ROS, contrasting reports on association of reduced production of the antioxidant enzyme, catalase has also been linked to iron deficiency-related ROS elevation, both in vivo and in vitro, thus fabricating a reconstructed pro-tumour redox balance, promoting their invasion and therapy resistance.\textsuperscript{33,34} This has again been paradoxically attributed to ROS-induced lipid peroxidation that causes DNA adducts driving loss of cell membrane integrity and has ultimate serious implications in cancer progression.\textsuperscript{21}

Emanating from an imbalanced pro-oxidant and antioxidant setting, oxidative stress, therefore remains one of the critical components in states of iron deficiency and overload, thus extending its effects on several pathophysiological and chronic complications, including malignancy.\textsuperscript{4,35,36} As one of the major drivers of iron deficiency, oxidative stress principally targets erythrocytes due to their oxygen-carrying ability, enforcing immediate erythrocyte loss through eryptosis.\textsuperscript{35} Eryptosis along with increased oxidative damage through higher phospholipid externalisation was reported in patients co-affected with type II diabetes mellitus and chronic kidney disease (CKD), highly predisposed to developing liver, pancreatic, bladder, breast and colon cancers.\textsuperscript{37–39} Furthermore, reports of increased eryptosis have been outlined in lung cancer, myelodysplastic syndrome and intestinal tumours in mice.\textsuperscript{40–42} However, iron deficiency might not be the sole contributor to oxidative stress.\textsuperscript{43} For example, under conditions of chronic inflammation, iron absorption gets significantly reduced as a defence strategy for iron deprivation...
to iron-feeding microbes to control their survival through impairment of ROS detoxification. Irrespective of the cause, symptomatic anaemia is treated as simply a state of iron deficiency and clinically counteracted by dietary, parenteral and/or enteral iron supplementation and blood transfusions, to restore iron stores for erythropoiesis.

Iron supplementation strategies, however, require the knowledge of underlying causes of iron deficiency in patients, through a series of iron determination tests listed under Table 1, to evade negative effects of iron build up, which might otherwise increase iron overload-associated risks. There have been few reports highlighting risks of iron accumulation resulting from excess iron ingestion as a part of diet or supplements. By 1989, physicians/doctors reported excessive iron as a potent risk associated with cancer, at levels significantly lower than estimated safe in the past. This was later supported by nutritionists recommending limiting consumption of iron-rich fortified foods, to avoid its over-absorption in the body. Evidences of clinical iron overload in adults taking daily iron supplements for 7, 15, 35 and 61 years showed a heterogeneous HFE-based phenotypical and genotypical association. Another study reported ferritin elevation in a postmenopausal Caucasian female, pre-treated for breast cancer, supplemented with a daily oral dose of 325–975 mg ferrous sulphate for three decades, despite no records of HFE mutation and chronic liver disease. Diet-induced iron overload risks have also been confirmed through epidemiological and meta-analytical evidence reporting positive correlation between excess red and processed meat.
| Diagnostic variables | Significance in body iron detection | Advantages | Limitations |
|----------------------|-----------------------------------|------------|-------------|
| Serum ferritin        | Iron storage marker and an acute phase reactant. Measures stored iron in liver and spleen. | Inversely correlates with iron assimilation in erythrocytes, cut-offs for which, vary considerably among experts. Limited evidence suggests that a serum ferritin > and < than 15 μg/L marks high and low iron stores, respectively in patients aged over 5 years. | Sensitive only until body iron stores are depleted and is significantly influenced by infection and inflammation. May be independent of changes in iron stores, thus challenging the interpretation of infection-driven body iron index. False normal levels may appear in cancer and other chronic conditions. |
| Soluble transferrin receptor (sTfR) | Regulates Fe-Tf uptake by erythrocytes. Measures biologically available iron. | Marks the magnitude of erythropoiesis and iron requirement in the body. sTfR levels increase with depletion of iron reserves in IDA, indicating severe iron deficit, therefore, applicable for FID estimation, post iron store depletion. | Remains a critical erythropoietic determinant. sTfR-logarithmic ferritin ratio opted as a promising index to determine changes in both iron stores and functional iron. The sTfR-ferritin determination, however, includes high cost and lack of normalisation. |
| Transferrin saturation (TSAT) | TSAT < and > 20% indicate iron deficiency and overload, respectively. Measures the number of iron-binding sites on Tf-Fe. | May be applied to uninflamed patients to identify a normal iron supply to tissues and bone marrow. | Remains an older diagnostic tool, due to its sensitivity to inflammation. |
| Hepcidin | Hepatic peptide which acts by binding to FPN. High plasma hepcidin indicates iron-restricted anaemia, including anaemia associated with inflammation, CKD and metastasis in cancers. Deficient hepcidin leads to iron overload conditions in HH, and inefficient erythropoiesis. Systemic hepcidin production is transcriptionally coordinated by plasma iron content, leading to its overproduction in conditions of iron abundance. | Preferred in clinical applications for erythrocytic iron assimilation. | Greatly affected by a range of stimuli, such as hypoxia and/or inflammation, thus making it a dynamic component. |
| Diagnostic variables | Significance in body iron detection | Advantages | Limitations |
|----------------------|-------------------------------------|------------|-------------|
| • Total iron-binding capacity (TIBC) | Measures serum Tf (apo, mono and diferric) responsible for iron transport to RBCs or body stores. | Tool in immunological assays used for iron status determination. | May appear as false deficient in conditions of coexisting acute and chronic infections. False normal levels may appear due to hypoproteinaemia. |
| • Gamma-glutamyl transpeptidase/gamma-glutamyltransferase (GGT) | A liver enzyme involved in glutathione metabolism and transport of amino acids and peptides. Correlates with iron toxicity, disease risk and mortality. | Early predictive marker for a multitude of chronic diseases. | Significantly altered in a wide range of diseases and dependent on several iron markers, hence cannot be used as a single-point measurement. |
| • Complete blood count (CBC) | Measures RBC, white blood cells (WBC), platelet count, Hb and haematocrit (Hct). Also includes • mean corpuscular volume (MCV) as a characteristic to RBC size, • mean corpuscular Hb concentration (MCHC), indicating Hb amount per RBC. | Evaluates overall health and underlying diseases. MCV determines the underlying aetiology of specific anaemia type. | Individually unable to assess acute changes in iron availability, secondary to ESA therapy. Iron replenishment from RBC pool gets significantly compromised causing suboptimal iron supply to erythroid marrow due to iron store depletion. Insufficient iron supply causes impairment of Hb production, thus leading to low MCHC detectable post weeks of Hb decline. |
| • Serum erythropoietin concentration | Principal regulator of RBC production. Correlates with body iron, serum unsaturated iron-binding capacity and ferritin in haemodialysis patients | Identifies the underlying causes of blood conditions. | Iron or vitamin deficiencies in patients may interfere with results. |
| • Percentage of hypochromic red cells (% HRC) | Provides an accurate determination of FID and latent iron deficiency (LID) through the Hb production by RBCs and reticulocytes. | A long-life span of mature circulating RBCs allows iron status of RBCs. Iron-restricted erythropoiesis can be determined by %HRC in ACD patients. | Analysis must be done in a fresh sample to avoid errors resulting from RBC swelling. |
| • Reticulocyte haemoglobin content (Chr) | Predicts FID in patients undergoing ESA therapy, determining response to intravenous iron administration in CKD patients, independent of acute phase. | Cost-effective diagnostic factor for early detection of iron availability for erythropoiesis alongside quality assessment of reticulocytes. | Lacks consistency in cut-off values determining outcomes in patients, therefore requiring further investigation. |
ingestion and increased risks of gastric, colorectal, prostate, lung, breast cancers and renal cell carcinoma, including other chronic disorders like coronary heart failure in patients with type II diabetes.74–80 Higher red meat intake in premenopausal women has also been observed to increase progesterone and oestrogen receptor positive breast cancer risks.81 Moreover, excessive red meat consumption (seven times per week) in subjects with elevated Tf levels has been associated with higher mortality.82 Red meat car-

TABLE 1 (Continued)

| Diagnostic variables | Significance in body iron detection | Advantages | Limitations |
|----------------------|-------------------------------------|------------|-------------|
| • RBC protoporphyrin | Measures compromised iron supply in peripheral RBCs. | Reflects iron supply during RBC production, derived through its accumulation in RBC precursors as a response to low iron. | Accumulation of its levels are also recorded for lead poisoning, hence requires exclusion to lead exposure. Its levels are also raised only several weeks post low-iron erythropoiesis. |
| • Zinc protoporphyrin | Stable screening marker for iron deficiency measured through systemic iron supply to bone marrow erythrocytes. | Instant, sensitive and cost-effective measurement and can be used in combination with haemoglobin concentrations for assessment of iron status in population-based studies. | Its evaluation in iron-deficiency associated with certain chronic diseases such as uraemia is mainly derived from cross-sectional studies, and hence, may produce conflicting results, therefore failing to validate its significance as a determinant in such chronic conditions. |
| • Bone marrow aspiration with iron staining | Evaluative measure for elimination of condition of IDA rather than a diagnostic factor. | Used as a confirmatory test in conditions where low TSAT and ferritin levels are at borderline levels associated with disorders other than IDA | Invasive, and decreased predictive accuracy from bone marrow samples with low or unavailable iron in bone marrow samples. |

Abbreviations: ACD, Anaemia of chronic diseases; CKD, chronic kidney disease; CBC, complete blood count; ESA, erythropoiesis-stimulating agent; FPN, ferroportin; FID, functional iron deficiency; GGT, gamma-glutamyl transpeptidase/gamma-glutamyltransferase; Ht, haematocrit; HH, hereditary hemochromatosis; IDA, iron deficiency anaemia; LID, latent iron deficiency; MCHC, mean corpuscular Hb concentration; MCV, mean corpuscular volume; % HRC, percentage of hypochromic red cells; RBCs, red blood cells; CHr, reticulocyte haemoglobin content; sTfR, soluble transferrin receptor; TIBC, total iron-binding capacity; Tf, transferrin; TSAT, transferrin saturation; WBC, white blood cells.

Taken together, the conflicting role of iron-driven ROS acts synergistically, posing a challenge in cancer therapeutic success, owing to the undefined intersections of states of iron deficiency and overload. While antioxidant therapies aimed towards ROS downregulation are available, they have been shown to enhance metabolic syndromes, along with increased cancer risks and patient mortality.89 These outcomes might be attributed to the antioxidant conditions being exploited by cancer stem cells (CSCs) to survive in a tumour microenvironment through minimising DNA damage and promoting metastasis.80 This mechanism is chemotherapeutically targeted through increasing ROS and inhibiting the antioxidant machinery in cancer cells.91 However, reports on ROS-independent chemotherapy have questioned the facet of ROS being a direct effector of cell
Anaemia as defined by the World Health Organisation (WHO) is a 'a condition represented by inadequate quantity of RBCs or their oxygen-carrying ability to suffice the physiological requirements of the body.' Iron deficiency anaemia (IDA), one of the most established types of anaemia is characterised by iron levels less than required for normal physiological functions, with symptoms including fatigue, appetite loss, dyspnea, pale skin, shortness of breath and headache. According to a global survey in 2010, one-third of the population was affected by anaemia with approximately 50% of the cases stemming from iron deficiency. The diagnostic cut-off criteria for IDA in terms of Hb levels, recommended by WHO, ranges from >10–11.5 g/dl to >12.5–13.8 g/dl in females and males respectively. IDA’s complex pathogenesis might be driven by a lowered erythropoietin response, decreased RBC survival along with reduced iron absorption and macrophageal iron retention, limiting iron delivery to erythroid precursor cells.

Anaemia and cancer, although being separate health conditions have often been linked, due to the ability of cancer cells to sequester iron, thereby limiting iron availability for RBC production. Anaemia is characteristically prevalent in cancer patients, of practically all cancer types to varying grades, resulting in low quality of life and poor prognosis. A single-centre study on patients with solid tumours and hematologic cancers revealed iron deficiency and anaemia in 42.6% and 33% of the subjects, respectively, with highest iron deficiency rates in pancreatic, colorectal and lung cancers. Cancer-related anaemia can be a direct consequence of cancer invasion, intrinsic or iatrogenic blood loss, radiation or chemotherapy, bone marrow failure, necrosis or inflammation. Besides, secondary or myelophthisic anaemia may result from cancer invasion-driven blood loss, erythropoiesis inhibition through tumour marrow infiltration (TMI), or inflammation leading to FID.

TMI is responsible for cancer relapse post-treatment, attributed to dormant cancer cell population leading to minimal residual disease, predicted to be driven by migration of disseminated cancer cells to bone marrow, thus posing challenges to the clinical cancer diagnosis. TMI-driven tumour recurrence was corroborated in a recent investigation indicating a rapid cancer relapse with brain metastatic lesion in a patient originally diagnosed with stage III rectal cancer. Incidentally, another equivalent criterion in cancer-associated anaemia stems from CIA, comprising a combined action of TMI, blood loss and erythropoiesis inhibition, synergistically co-driving normal cells into a state of malignancy, as a reaction to inflammation. Evidence on the higher incidence and relative risks (RR) of anaemia induced by appropriate cornerstone chemotherapeutics have been reported in lung and pancreatic cancer patients subjected to tyrosine kinase inhibitors namely erlotinib and gefitinib. Besides, low- and high-grade anaemia incidence in breast cancer patients, ranging between 1% and 80%, has also been associated with mainstream combination chemotherapy including 5-fluorouracil, doxorubicin, etoposide, mitoxantrone, methotrexate and cyclophosphamide. While iron deficiency has also been reportedly associated to the development or recurrence of certain types of malignancies, such as gastrointestinal carcinomas, lung, urinogenital and premenopausal breast cancer, mild to acute CIA (Hb level <10 g/dl) has been reported in patients affected with solid tumours in breast, colon/rectum, lung, ovary and stomach. Another study with a set of cancer patients undergoing chemotherapy reported chemotherapy-driven iron loss in 75% of the subjects, with 60% of them diagnosed with AID monitored through low ferritin. CIA, however, is dependent on tumour grade, type and patient’s heart and lung conditions and their exposure to prior anticancer therapies, thus favouring personalised treatments accompanied by management of nutritional deficiencies. These reports were validated in a study on a range of cancer victims receiving chemotherapy, in which grade 2+ (Hb <10 g/dl) CIA incidence ranged from about 26% to 59% in colorectal and ovarian cancer, respectively, whereas severe anaemia (Hb <8 g/dl) was maximum in ovarian cancer (about 17%) and minimum in colorectal cancer (4%). Additionally, there was an overall increase of about 1.7-fold in grade 2+ CIA risk in stage I to IV transition.

Furthermore, chemotherapy-induced IDA is a common contributor to renal injury or CKD, resulting through tumour invasion or as an age-driven atrophy in elderly cancer patients. IDA in CKD or end-stage renal disorder (ESRD) patients undergoing haemodialysis, develops as a result of imbalanced intestinal iron absorption, chronic inflammations, blood loss and iron overutilization for erythropoiesis spiked through erythropoiesis-stimulating factors.
agents (ESA).\textsuperscript{112} Unstable body iron indices in such patients make it challenging to accurately determine the iron status, due to possible coexistent inflammations or infection and conditions of comorbidity.\textsuperscript{113} ESA dosage optimisation through use of intravenous (IV) iron in CKD following haemodialysis, for chronic anaemia management escalated since 1990, owing to improved outcomes, ease of administration and infrequent adverse concerns, leading to its rapid adoption in the standard treatment procedure.\textsuperscript{114} However, since iron regulation is a closed system lacking an active excretory channel and predominantly controlled by hepcidin, chronic IV iron therapies may pose a risk of iatrogenic iron overload, as reported in a chemotherapeutically treated 56-year-old breast cancer patient diagnosed with ESRD.\textsuperscript{115,116} Despite being clinically asymptomatic to iron overload-induced organ failure, a significantly high iatrogenic iron level was observed as a response to IV iron supplementation for treating kidney transplantation-associated FID.\textsuperscript{116} Furthermore, IV iron has been reported to increase free iron pool in circulation or tissues through saturation of iron-binding sites of ferritin and Tf, thus enhancing oxidative injury, mitochondrial damage and cytotoxicity as observed in vitro, in vivo and clinically.\textsuperscript{114,117,118} A recent investigation revealed a concomitant increase in hepatic iron concentration in ESRD patients undergoing dialysis subjected to IV therapy, otherwise observed to significantly decrease on its withdrawal or considerable dose reduction.\textsuperscript{119} However, while contrasting evidence on IV iron therapies significantly reducing risks of transfusion-based iron overload are available, therapy-induced erythropoiesis tends to utilise bioavailable functional body iron, creating an iron-restricted environment, further worsening FID in haemodialysis patients through constant increasing free iron demands.\textsuperscript{115,120,121} Altogether, the clinical use and long-term safety of ESA and IV iron therapies remain controversial.\textsuperscript{114,115} Relevant reports revealing haemosiderosis in patients undergoing dialysis resulted in re-investigation of iron overload risks in CKD patients suffering from ESRD and inflammatory bowel disease (IBD), as a response to iron supplements authorised for marketing.\textsuperscript{115} Furthermore, long-term safety of these therapies was challenged due to a lack of randomised clinical trials with multiple dosage protocols and insufficient and contradictory answers to their efficacy, confirming that the frequency of accumulative iron exposure may be extensively underestimated in haemodialysis patients.\textsuperscript{115} Collectively, an oversimplification of heterogeneous IV iron treatment course in haemodialysis patients reveal that progressive iron exposures may not orient well with iron administration strategies in clinical practises.

Nonetheless, with anaemia simply stemming from a multitude of factors responsible for hindering oxygen delivery to tissues, it is noteworthy that while anaemia is not a sole indicator of cancer, it might develop as an independent or a combined outcome of the disease itself or its therapy. Anaemia in cancer patients, therefore, might not be a direct outcome of cancer, thus making anaemia a symptom rather than a direct diagnostic factor. Besides, anaemia initiating as a stress erythropoietic event may transition to a state of iron overload through concurrent hepcidin decrease, thus revealing an inevitable link between the two states.\textsuperscript{122} Moreover, conditions of anaemia do not necessarily indicate blood transfusions or iron supplementation, which if unchecked, may cause consequential superfluous risks of iron overload, an argument that has been elaborately discussed below, in terms of chronic infections, including cancer.

5  |  IRON OVERLOAD IN CANCER

Iron overload has been widely associated with chronic diseases or pathologies, such as, liver cirrhosis, haemochromatosis, heart failures, type II diabetes, neurodegenerative diseases and cancer, particularly hepatocellular, colon, colorectal, breast, prostate, pancreatic, bladder and lung cancers.\textsuperscript{123,124} While not much has yet been elucidated on the fundamental effects of iron overload in driving tumorigenesis apart from iron overload-induced oxidative stress-driven DNA damage and lipid peroxidation, there exists an elementary explanation to the direct association of iron overload to chronic infections, including cancer. Infection is an inter-tissue entry of pathogenic microbes in multicellular hosts.\textsuperscript{125} Under healthy conditions, iron is stored in proteins like Tf and lactoferrin as a host defence strategy to restrain its availability to pathogens.\textsuperscript{125} Conversely, patients with clinical iron overload are susceptible hosts to lethal infection causing microbiota, such as Escherichia coli, Vibrio vulnificus and Yersinia enterocolitica, possessing a tendency of iron sequestration from host body in exchange of rapid growth.\textsuperscript{125} Iron supplementation significantly increases unabsorbed soluble free iron, which may be utilised by potentially pathogenic microbial strains to initiate or aggravate infection.\textsuperscript{125} This was revealed in a set of Ivorian subjects fed with iron-fortified biscuits resulting in a remarkable increase in pathogenic Enterobacteria strain along with a growth retardation in beneficial Lactobacilli and Bifidobacteria strains.\textsuperscript{126} Moreover, higher levels of calprotectin, a gut inflammatory marker were observed in this group’s faeces, validating the link between excess iron and inflammation.\textsuperscript{126} Besides, epidemiological evidence suggests a direct association of high serum iron and ferritin with infections progressing to cancer risks, rendering patients less likely to recover and develop treatment resistance.\textsuperscript{127,128}
Infection-associated chronic iron overload has also been reported to drive secondary hemochromatosis, a potent cancer antecedent, also significantly affected by oral iron intake. With elemental iron proven to be toxic at an oral dosage of over 60 mg/kg, excess dietary iron has been associated with increased systemic levels of heme and non-heme iron along with circulating free/ferrous ions in the body. Moreover, the evidence of association of oral iron to cancer risks dates as early as 1990s, reported in prospective animal studies revealing incidence of colorectal, hepatic, renal tubular cell carcinomas and sarcomas. While related experimental evidence on human subjects were earlier deemed unethical, genetic defects on oral iron assimilation have been proved to be a source of hepatic and non-hepatic iron overload in certain populations (Whites and sub-Saharan Africans), as a result of hereditary hemochromatosis. However, while hemochromatosis in white populations (North Europeans, Australians predominately Caucasians and French), with no evidence of inbreeding is generally inherited through \textit{HFE} gene in \textit{HLA} locus, iron overload conditions in sub-Saharan African population has been believed to result solely due to increased intake of traditional home-brewed beer, rich in non-heme iron. Moreover, emerging evidence on hemochromatosis patients has indicated ferritin’s role in states of severe shock, causing its rapid release into circulation thus establishing a possible link between iron overload shocks and resulting infections. Additionally, hemochromatosis-driven iron overload induces epigenetic modification as an initiating event in malignancy. In response, excess labile iron pool significantly stimulates cancer cell metastasis, as demonstrated in breast cancer through heme oxygenase-1 (HO-1) expression.

Besides, an increased probability of iron overload risks has been recently established, as a repercussion of iron administration in populations, where iron deficiency was not a causative factor of anaemia. An ongoing study targeting childbearing-aged Cambodian women highly susceptible to inherent and iron supplementation-driven iron overload risks due to genetic Hb disorders aims to distinctively determine the effects of common and newer iron supplements, namely ferrous sulphate and ferrous bisglycinate, respectively on ferritin levels and inflammation. While the study results are pending, its objective remains highly significant to validate the safety and efficacy of iron supplements, as successfully revealed by an earlier study showing improved haematological profile, decreased inflammation and unaffected oxidative stress in anaemic pregnant females supplemented with 120 mg/day of elemental iron as opposed to higher oxidative stress and inflammation in non-anaemic pregnant females exposed to half the dose. While serum ferritin remained unaltered in the non-anaemic category, the study reflected upon iron overload toxicity as a possible cause of elevated radical generation and inflammation identified as potent initiators of malignancy.

Elevated free radical generation as a response to iron overload promotes cancer cell survival and metastasis by causing genetic aberrations and mitochondrial dysfunction acting in tandem or independently. Therapy resistance, one of the principal strategies of cancer cell survival has been associated with ROS-driven dysfunction in mitochondrial morphology and downregulation of the mitochondrial enzyme, pyruvate dehydrogenase, along with epithelial to mesenchymal transition (EMT), reported in gefitinib-resistant lung adenocarcinoma H1650 clones. Moreover, iron-induced ROS-driven overexpression of a reported metastatic and prognostic cancer marker, caveolin-1, known to promote resistance to chemotherapeutic-induced apoptosis, was reported in H460 lung carcinoma, on exposure to ferrous sulphate. Furthermore, with CSCs being considered as the primary sub-population responsible for cancer relapse, metastasis and therapy resistance, recent investigations have reported the role of iron not only in promoting tumorigenesis, but also stemness in tumour cells, as has been validated by an elevated \\textit{Trk1} expression in breast CSCs as compared to differentiated cancer cells. The survivability of CSCs is attributed to the presence of an integral antioxidant machinery, CD44 marker variant, to help them maintain low levels of intracellular ROS to evade their toxic effects. Moreover, the involvement of CD44, being a promoter of EMT, indicates the role of iron in the tumorigenesis transition. EMT is responsible for loss of cell adhesion and polarity through downregulation of epithelial marker, E-cadherin, while upregulating certain mesenchymal and motility markers such as Snail, TWIST, N-cadherin and vimentin. Iron deprivation has been shown to reverse the EMT process, as validated by significant downregulation of E-cadherin in KM12C colon cancer cell as a response to an iron-regulatory protein, neutrophil gelatinase-associated lipocalin (NGAL)/lipocalin2. Moreover, while excess iron in the form of ferric chloride was able to upregulate ferritin levels in NGAL overexpressing KM12C cells, deferoxamine (DFO), an established iron chelator, was able to significantly reduce the ferritin concentration to undetectable limits. These factors collectively portray iron overload as either a causative factor or an outcome of malignancy, irrespective of its source, including unsought iron administrations, iron-rich diet, history of chronic diseases or genetic imbalances in iron-regulatory system.

Taken together, although the speculation of iron’s role in cancer is a labyrinth of several factors, the interdependence of iron deficiency and overload in a heterogeneous tumour environment cannot be disregarded. While not much validation is available on the iron-restoration
therapies driving conditions of iron overload in cancer patients, interestingly, appearing as a symbiotic relationship, relevance of judicious monitoring of iron markers in anaemic patients, prior to opting for iron reinstating strategies, must be emphasised. One of the major requisites to evade undesirable iron accumulation as a response to administered iron is, therefore, to critically identify the possible intersections of both states of iron deficiency and overload, one of the key hindrances to successful therapies in iron-associated cancer.

6 | TARGETING IRON METABOLISM FOR CANCER THERAPY

As mentioned earlier in this review, with iron deficiency and overload interplaying conjointly in a cancer patient at varied points, it appears to generate a rather puzzling condition hindering the identification of the exact target for cancer therapy without jeopardising a patient’s health. A detailed understanding of the patient’s underlying status of iron is, therefore, crucial in order to create a personalised chemotherapeutic regimen.

For instance, if AID has been identified as a potential cause for iron deficiency in a cancer patient, a favourable therapy regimen must include newer or combination therapeutics maintaining lower anaemia incidence and risk rates. One such example has been reported in a meta-analytical study involving solid tumour patients exposed to appropriate chemotherapeutics alone and in combination with a humanised monoclonal antibody (bevacizumab), with bevacizumab able to significantly reduce both incidence and risk rates of anaemia in a dose-dependent manner, as compared to chemotherapy alone. However, with chemotherapy-related anaemia being a frequent symptom in cancer patients and lack of extensive research on the pathogenetic mechanisms of anaemia development as a response to chemotherapeutics, information on antianaemic therapies remains limited. Particularly, chemotherapy-induced lower grade anaemia appears to be more frequent than higher grade anaemia, usually requiring a blood transfusion. With no approved treatments available for correction of mild anaemia, the only options available for iron restoration remain chemotherapy interruption, iron administration and blood transfusion. However, long-term iron administrations and blood transfusions may lead to iron deposition in organs eventually enabling iron accumulation in circulation to toxic levels potentially causing a risk of chronic infection, including carcinogenesis. Recombinant human erythropoietin namely epoetins in combination with chemotherapeutics have been approved as alternatives for correction of anaemia in patients harbouring non-myeloid tumours, in order to reduce the number of blood transfusions in a cancer patient. Regardless, the risks of iron overload as a response to iron restoration remains a concern in patients merely affected by FID. While use of iron chelators alone and in combination have been widely recognised to check unwanted iron overload in cancer patients, with their role attributed to enhance miRNA precursor processing and upregulate expression and function of tumour suppressor proteins, some of the chelators, namely deferiprone holds a redox potential capable of generating intracellular ROS. Although this might be a favourable step towards driving ferroptosis acting against cancer cells, there have been limited evidence on the success of iron chelators on solid tumours, the reason accredited to their response towards stabilisation and enhanced expression of hypoxia inducible factor-1 alpha (HIF-1α), further aiding tumour proliferation, metastasis and angiogenesis.

An effective strategy for treatment of solid tumours, therefore, indicates a possible addition of HIF-1α inhibitor to iron chelation therapy, as reported in one of the studies exploiting a combination of DFO and HIF-1α inhibitor (lificiguat/YC1) exhibiting a synergistic antitumour effect on pancreatic tumours in vitro and in xenograft mice models. Nonetheless, it is noteworthy that cancer is a genetic disorder displaying multiple identified and unidentified abnormalities in cellular metabolism. While dysregulated iron metabolism is one of the features in cancer cells driving heightened influx and decreased efflux of iron from tumour cells, it is unclear if this imbalance precedes the cancerous transformation or is a consequential response to cancer, aiding as an adaptive step for maintenance and progression of malignancy. With multiple iron-dependent paradoxes simultaneously playing differential role in different cancer types and patients, and existing limitations and concerns for each iron modulation approach, it is confusing whether the best possible approach for its therapy lies in inhibition of iron usage or to enhance iron flooding to induce ferroptosis, thus rendering it challenging to identify which patients are most likely to respond to a given therapy. Furthermore, development of novel iron-based therapeutics remains rigorous owing to their toxicity, rapid metabolism, short half-lives and increasing resistance of cancer cells.

7 | CONCLUSION

While iron and ROS are key factors in cellular homeostasis, their disrupted regulation act as a driver in tumorigenesis. Stemming from the dual role of iron in cancer, both states of iron deficiency and overload play a major role in the
disease itself, as well as present themselves as an unavoidable treatment-associated risk. The complexity to decipher the exact functioning of iron as a pro-cancer or anticancer factor synergistically acts with the puzzling states of iron deficiency and overload in chronic complications, including cancer. Moreover, for majority of physicians, the primary concern in terms of ‘iron’ till date, remains anaemia or simply a state of iron deficiency, without comprehending ‘iron overload’ as a more prevalent and leading issue, and substantially more life-threatening, leading to a myriad of complications. Although a frequent symptom, pathogenesis of iron deficiency, yet remains poorly addressed in patients with cancer and other chronic infections along with individuals genetically predisposed to iron overload. Unmethodical red cell transfusions and iron supplementation established as default treatment strategies for iron deficiency may open a ‘Pandora’s box’, promoting unwanted risks of iron overload, a precursor to tumorigenesis and a condition that is often overlooked. Hence, a detailed understanding of the iron status in patients prior to anticancer or iron-restoration therapies is a critical requirement to evade exacerbation of a pre-existing condition. Moving forward, an individualised treatment of iron deficient patients might be preferably opted for, which requires a detailed diagnostic evaluation of iron deficiency and its origin by routine blood testing prior to iron supplementation.

ACKNOWLEDGEMENT

The authors would like to acknowledge Prof. Jagat R. Kanwar for his impactful supervision and sharing his expertise on molecular oncology in framing the initial outline for this manuscript.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTION

Tulika Basak has contributed to the review article’s conceptualisation, literature search, draft preparation, review and editing. Rupinder Kaur Kanwar has contributed to the review article’s conceptualisation, literature search, draft revisions and editing. Both authors have read and agreed to the published version of the review article.

ETHICAL APPROVAL STATEMENT

This is a review article based on published literature; no human/animal participation or cell-based work involved. Ethical statement is not applicable.

DOCUMENTATION OF INFORMED CONSENT/CLINICAL TRIAL REGISTRATION/REVIEW BOARDS

Not applicable for this review article.

DATA AVAILABILITY STATEMENT

Data sharing is not applicable to this review article as no new data were created or analysed. The article, however, contains a table and three schematic figures, which are original and have been created by the authors through reviewing the information, pooled from the already published literature/journal articles. All the references have been duly cited in this manuscript. No third-party material (figures or tables) has been included in the current article.

ORCID

Tulika Basak https://orcid.org/0000-0002-1852-7455

REFERENCES

1. Khan A, Singh P, Srivastava A. Iron: Key player in cancer and cell cycle?! Trace Elem Med Biol. 2020;62:126582.
2. Wallace DF. The regulation of iron absorption and homeostasis. Clin Biochem Rev. 2016;37(2):51-62.
3. Jian J, Yang Q, Dai J, et al. Effects of iron deficiency and iron overload on angiogenesis and oxidative stress-a potential dual role for iron in breast cancer. Free Radic Biol Med. 2011;50(7):841-847.
4. Bystrom LM, Rivella S. Cancer cells with iron in the fire. Free Radic Biol Med. 2015;79:337-342.
5. Busti F, Marchi G, Ugolini S, Castagna A, Girelli D. Anemia and iron deficiency in cancer patients: Role of iron replacement therapy. Pharmaceuticals. 2018;11(4):94.
6. Ganz T. Iron and infection. Int J Hematol. 2018;107(1):7-15.
7. Innih SO, Iorliam EB, Lawal TE. Effects of tetracarpidium concophorum on iron overload-induced cardiac toxicity in Wistar rats. Int J Pharmacol, Phytochem Ethnomed. 2021;16:33-41.
8. Lane DJR, Bae D-H, Merlot AM, Sahni S, Richardson DR. Duodenal cytochrome b (DCYTB) in iron metabolism: an update on function and regulation. Nutrients. 2015;7(4):2274-2296.
9. Cronin SJF, Woolf CJ, Weiss G, Penninger JM. The role of iron regulation in immunometabolism and immune-related disease. Front Mol Biosci. 2019;6:116.
10. Ohgami RS, Campagna DR, Greer EL, et al. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat Genet. 2005;37(11):1264-1269.
11. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17):4425-4433.
12. Yeh KY, Yeh M, Glass J. Interactions between ferroportin and hephaestin in rat enterocytes are reduced after iron ingestion. Gastroenterology. 2011;141(1):292-299.
13. Sangkhae V, Nemeth E. Regulation of the iron homeostatic hormone hepcidin. Adv Nutr. 2017;8(1):126-136.
14. Macciò A, Macheddù C, Gramignano G, et al. The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. Haematologica. 2015;100(1):124-132.
15. Naoum FA. Iron deficiency in cancer patients. Rev Bras Hematol Hemoter. 2016;38(4):325-330.
16. Khan AA, Hadi Y, Hassan A, Kupec J. Polycythemia and anemia in hereditary hemochromatosis. Cureus. 2020;12(4):e7607.
17. Johnson MB, Enns CA, Zhang A-S. Iron in mammals: Pathophysiological mechanisms of overload and deficiency.
in relation to disease. In: Tamas M.J.M.E. ed. Molecular biology of metal homeostasis and detoxification. Springer; 2005:155–191.

18. Townsend A, Drakesmith H. Role of HFE in iron metabolism, hereditary haemochromatosis, anaemia of chronic disease, and secondary iron overload. *Lancet*. 2002;359(9308):786-790.

19. Forciniti S, Greco L, Grizzi F, Malesci A, Laghi L. Iron metabolism in cancer progression. *Int J Mol Sci*. 2020;21(6):2257.

20. Winn NC, Volk KM, Hasty AH. Regulation of tissue homeostasis: the macrophage “ferrostat”. *JCI Insight*. 2020;5(2):e132964.

21. Gammella E, Recalcati S, Cairo G. Dual role of ROS as signal and stress agents: iron tips the balance in favor of toxic effects. *Oxid Med Cell Longev*. 2016;2016:8629024-8629029.

22. Aschemeyer S, Qiao B, Stefanova D, et al. Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin. *Blood*. 2018;131(8):899-910.

23. Gkamprela E, Deutsch M, Pectasides D. Iron deficiency anemia in chronic liver disease: etiopathogenesis, diagnosis and treatment. *Ann Gastroenterol*. 2017;30(4):405.

24. Anderson ER, Shah YM. Iron homeostasis in the liver. *Compr Physiol*. 2013;3(1):315-330.

25. Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. *Hypoxia (Auckland, NZ)*. 2015;3:83-92.

26. Galadari S, Rahman A, Fallichkandy S, Thayyullathil F. Reactive oxygen species and cancer paradox: to promote or to suppress? *Free Radical Biology and Medicine*. 2017;104:144-164.

27. Thomas C, Mackey MM, Diaz AA, Cox DP. Hydroxyl radical is produced via the Fenton reaction in submitochondrial particles under oxidative stress: implications for diseases associated with iron accumulation. *Redox Rep*. 2009;14(3):102-108.

28. Che M, Wang R, Li X, Wang H-Y, Zheng XFS. Expanding roles of superoxide dismutases in cell regulation and cancer. *Drug Discov Today*. 2016;21(1):143-149.

29. Lu B, Chen XB, Ying MD, He QI, Cao J, Yang B. The role of ferroptosis in cancer development and treatment response. *Front Pharmacol*. 2017;8:992.

30. Jiang M, Qiao M, Zhao C, Deng J, Li X, Wang H-Y, Zheng XFS. Expanding roles of iron accumulation. *Redox Rep*. 2020;9(4):1569-1584.

31. Alim I, Caulfield JT, Chen Y, et al. Selenium drives a transcriptional adaptive program to block ferroptosis and treat stroke. *Cell*. 2019;177(5):1262-1279.e1225.

32. Yang WS, Srisraramatnam R, Welsch ME, et al. Regulation of ferroptotic cancer cell death by GPX4. *Cell*. 2014;156(1–2):317-331.

33. Cockfield JA, Schafer ZT. Antioxidant defenses: A context-specific vulnerability of cancer cells. *Cancer*. 2019;11(8):1208.

34. Inoue H, Hanawa N, Katsumata S-I, Katsumata-Tsboi R, Takahashi N, Uehara M. Iron deficiency induces autophagy and activates Nrf2 signal through modulating p62/SQSTM1. *Biomed Res Int*. 2017;38(6):343-350.

35. Bissinger R, Bhuyan AAM, Qadri SM, Lang F. Oxidative stress, erythropoiesis and anemia: a pivotal mechanistic nexus in systemic diseases. *FEBS J*. 2019;286(5):826-854.

36. Rahal A, Kumar A, Singh V, Yadav B, Tiwari R, Chakraborty S, Dhamaka. Oxidative stress, prooxidants, and antioxidants: The interplay. *Biomed Res Int* 2014;2014:761264.
of anemia in chronic kidney disease- ESRD patients. *Biomed Pharmacother.* 2016;82:44-48.

56. Locatelli F. Appendix B: Assessment of iron stores and functional iron deficiency. *Nephrol Dial Transplant.* 2004;19(Suppl 2):39-41.

57. Amstad Bencaiová G, Krafft A, Zimmermann R, Burkhardt T. Treatment of anemia of chronic disease with true iron deficiency in pregnancy. *J Pregnancy.* 2017;2017:7.

58. Pagani A, Tai A, Silvestri L, Camachella C. Hepcidin and anemia: A Tight relationship. *Front Physiol.* 2019;10:1294.

59. Alageeli AA, Alqahtany FS, Algahtani FH. The role of reticuloocyte hemoglobin content for the diagnosis of functional iron deficiency in hemodialyzed patients. *Saud J Biol Sci.* 2021;28(1):50-54.

60. Cai J, Wu M, Ren J, et al. Evaluation of the efficiency of the reticuloocyte hemoglobin content on diagnosis for iron deficiency anemia in Chinese adults. *Nutrients.* 2017;9(5):450.

61. Ermens A, Hoffmann J, Krockenberger M, Van Wijk E. New erythrocyte and reticuloocyte parameters on CELL-DYN Sapphire: analytical and preanalytical aspects. *Int J Lab Hematol.* 2012;34(3):274-282.

62. Ganti AK, Moazzam N, Laroia S, Tendulkar K, Potti A, Mehdi SA. Predictive value of absent bone marrow iron stores in the clinical diagnosis of iron deficiency anemia. *In Vivo.* 2003;17(5):389-392.

63. Hönemann C, Hagemann O, Doll D, Luedi M, Ruebsam M, Meybohm P. Reticulocyte hemoglobin equivalent as a diagnostic marker for the current iron deficiency: Old wine in new bottles. *Anaesthesia.* 2020;69:919-925.

64. Koca E, Cetiner DA, Buyukasik Y, et al. Bone marrow iron staining is a reliable test for elimination of iron deficiency anemia rather than its diagnosis. *Int J Hematol Oncol.* 2013;23(4):260-263.

65. Canavese C, Grill A, Decostanzi E, et al. Limited value of zinc protoporphyrin as a marker of iron status in chronic hemodialysis patients. *Clin Nephrol.* 2000;53(1):42-47.

66. Mwangi MN, Maskey S, Andang’o PE, et al. Diagnostic utility of zinc protoporphyrin to detect iron deficiency in Kenyan pregnant women. *BMC Med.* 2014;12(1):1-13.

67. Ingleson K. What to know about iron poisoning? Medical News Today. [https://www.medicalnewstoday.com/articles/318903#outlook](https://www.medicalnewstoday.com/articles/318903#outlook). Published 2017. Updated August 12, 2017. Accessed 26th November, 2021.

68. Lands R, Isang E. Secondary hemochromatosis due to chronic oral iron supplementation. *Case Rep Hematol.* 2017;2017:3.

69. Barton JC, Lee PL, West C, Bottomley SS. Iron overload and prolonged ingestion of iron supplements: clinical features and mutation analysis of hemochromatosis-associated genes in four cases. *Am J Hematol.* 2006;81(10):760-767.

70. Halliwell B. Tell me about free radicals, doctor: a review. *J R Soc Med.* 1989;82(12):747-752.

71. Schümann K. Safety aspects of iron in food. *Ann Nutr Metab.* 2001;45(3):91-101.

72. Martins JM. Universal iron fortification of foods: the view of a hematologist. *Rev Bras Hematol Hemoter.* 2012;34:459-463.

73. Breeden C. Nutrition support of hemochromatosis therapy. For people with hemochromatosis, their families, and health care providers. [https://azdhs.gov/documents/prevention/azwic/agencies/conferences/explore-the-possibilities-conference/2016/cathy-breeden-handouts/mnt-2-aunt-c-hemochromatosis-sanf-16-this-no-date-sanf.pdf](https://azdhs.gov/documents/prevention/azwic/agencies/conferences/explore-the-possibilities-conference/2016/cathy-breeden-handouts/mnt-2-aunt-c-hemochromatosis-sanf-16-this-no-date-sanf.pdf). Published 2016. Updated April, 2016. Accessed 27th July, 2020.

74. Zhu H, Yang X, Zhang C, et al. Red and processed meat intake is associated with higher gastric cancer risk: A meta-analysis of epidemiological observational studies. *PloS one.* 2013;8(8):e70955.

75. Alexander DD, Mink PJ, Cushing CA, Scurman B. A review and meta-analysis of prospective studies of red and processed meat intake and prostate cancer. *Nutr J.* 2010;9(1):50.

76. Qian F, Riddle MC, Wylie-Rosett J, Hu FB. Red and processed meats and health risks: How strong is the evidence? *Diabetes Care.* 2020;43(2):265-271.

77. Zhang S, Wang Q, He J. Intake of red and processed meat and risk of renal cell carcinoma: a meta-analysis of observational studies. *Oncotarget.* 2017;8(44):77942-77956.

78. Xue X-J, Gao Q, Qiao J-H, Zhang J, Xu C-P, Liu J. Red and processed meat consumption and the risk of lung cancer: a dose-response meta-analysis of 33 published studies. *Int J Clin Exp Med.* 2014;7(6):1542-1553.

79. Guo J, Wei W, Zhan L. Red and processed meat intake and risk of breast cancer: a meta-analysis of prospective studies. *Breast Cancer Res Treat.* 2015;151(1):191-198.

80. Micha R, Michas G, Mozaffarian D. Unprocessed red and processed meats and risk of coronary artery disease and type 2 diabetes–an updated review of the evidence. *Curr Atheroscler Rep.* 2012;14(6):515-524.

81. Cho E, Chen WY, Hunter DJ, et al. Red meat intake and risk of breast cancer among premenopausal women. *Arch Int Med.* 2006;166(20):2253-2259.

82. Mainous AG, Wells B, Carek PJ, Gill JM, Geesey ME. The mortality risk of elevated serum transferrin saturation and consumption of dietary iron. *Ann Family Med.* 2004;2(2):139-144.

83. Ems T, Huecker MRJS. Biochemistry, iron absorption. [Updated 2021 Apr 26]. In: StatPearls [Internet]. :StatPearls Publishing; 2021. Available from: [https://www.ncbi.nlm.nih.gov/books/NBK448204/](https://www.ncbi.nlm.nih.gov/books/NBK448204/).

84. Chai X, Li D, Cao X, et al. ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice. *Sci Rep.* 2015;5(1):10181.

85. Witte D, Bartscht T, Kaufmann R, et al. TGF-β1-induced cell migration in pancreatic carcinoma cells is RAC1 and NOX4-dependent and requires RAC1 and NOX4-dependent activation of p38 MAPK. *Oncol Rep.* 2017;38(6):3693-3701.

86. Al Tameemi W, Dale TP, Al-Jumaily RMK, Forsyth NR. Hypoxia-modified cancer cell metabolism. *Front Cell Dev Biol.* 2019;7:4.

87. Leone A, Roca MS, Ciardiello C, Costantini S, Budillon A. Oxidative stress gene expression profile correlates with cancer patient poor prognosis: Identification of crucial pathways might select novel therapeutic approaches. *Oxid Med Cell Longev.* 2017;2017:18.

88. Jun JC, Rathore A, Younas H, Gilkes D, Polotsky VY. Hypoxia-inducible factors and cancer. *Curr Sleep Med Rep.* 2017;3(1):1-10.

89. Salehi B, Martorell M, Arbiser JL, et al. Antioxidants: Positive or negative actors? *Biomolecules.* 2018;8(4):124.

90. Ding S, Li C, Cheng N, Cui X, Xu X, Zhou G. Redox regulation in cancer stem cells. *Oxid Med Cell Longev.* 2015;2015:11.

91. Asadi-Samani M, Farkhad NK, Mahmoudian-Sani MR, Shirzad H. Antioxidants as a double-edged sword in
92. Zhelev Z, Ivanova D, Bakalova R, Aoki I, Higashi T. Inhibition of the pentose-phosphate pathway selectively sensitizes leukemia lymphocytes to chemotherapeutics by ROS-independent mechanism. *Anticancer Res*. 2016;36(11):6011-6020.

93. Kotze M, Van Velden D, Van Rensburg S, Erasmus R. Pathogenic mechanisms underlying iron deficiency and iron overload: New insights for clinical application. *Ejifcc*. 2009;20(2):108-123.

94. Organization WH. *Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity*. World Health Organization; 2011. https://apps.who.int/iris/handle/10665/85839

95. Na HL. Iron deficiency anemia. *Clin Pediatr Hematol Oncol*. 2020;27(2):101-112.

96. Auerbach M, Gafter-Gvili A, Macdougall IC. Intravenous iron: A framework for changing the management of iron deficiency. *Lancet Haematol*. 2020;7(4):e342-e350.

97. Rose SD. Ensuring adequate iron status in vegetarians and vegans. *Adv Rest Gastroenterol Hepatol*. 2019;13(4):74-78.

98. Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. *Int J Mol Sci*. 2019;20(2):273.

99. Jung M, Mertens C, Tomat E, Brüne B. Iron as a central player of the pentose-phosphate pathway selectively sensitizes leukemia lymphocytes to chemotherapeutics by ROS-independent mechanism. *Anticancer Res*. 2016;36(11):6011-6020.

100. Ludwig H, Müldür E, Endler G, Hübl W. Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. *Ann Oncol*. 2013;24(7):1886-1892.

101. Ashorobi D, Munakomi S. Myelophthisic anemia. [Updated 2021 Aug 9]. In: StatPearls [Internet]; :StatPearls Publishing. 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK541103/.

102. Tjensvoll K, Nordgård O, Skjåkebøl M, Oltedal S, Janssen EA, Gilje B. Detection of disseminated tumor cells in bone marrow predict late recurrences in operable breast cancer patients. *BMC Cancer*. 2019;19(1):1131.

103. Thomopoulos K, Manolakou S, Messaritakis I, et al. Brain and bone marrow metastases from rectal cancer. *Ann Gastroenterol*. 2020;33(1):95-97.

104. Barni S, Cabiddu M, Guarneri P, Lonati V, Petrelli F. The risk for anemia with targeted therapies for solid tumors. *Hematol Oncol Clin North Am*. 2012;27(5):715-724.

105. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. *J Nat Cancer Inst*. 1999;91(19):1616-1634.

106. Xu H, Xu L, Page JH, et al. Incidence of anemia in patients diagnosed with solid tumors receiving chemotherapy, 2010-2013. *Clin Epidemiol* 2016;8:61-71.

107. Gaspar BL, Sharma P, Das R. Anemia in malignancies: Pathogenetic and diagnostic considerations. *Hematology*. 2015;20(1):18-25.

108. Jian J, Yang Q, Shao Y, et al. A link between premenopausal iron deficiency and breast cancer malignancy. *BCMC Cancer*. 2013;13:307.

109. Jajeh A. Iron deficiency anemia is common in patients receiving chemotherapy. *Blood*. 2015;126(23):4559.

110. Madeddu C, Gramignano G, Astara G, et al. Pathogenesis and treatment options of cancer related anemia: Perspective for a targeted mechanism-based approach. *Front Physiol*. 2018;9:1294.

111. Romano AD, Paglia A, Bellanti F, et al. Molecular aspects and treatment of iron deficiency in the elderly. *Int J Mol Sci*. 2020;21(11):3821.

112. Gluba-Brzózka A, Franczyk B, Oliszewski R, Rysz J. The influence of inflammation on anemia in CKD patients. *Int J Mol Sci*. 2020;21(3):725.

113. Gargallo-Puyuelo CJ, Alfambría E, García-Erce JA, Gomollón F. Iron treatment may be difficult in inflammatory diseases: Inflammatory bowel disease as a paradigm. *Nutrients*. 2018;10(12):1959.

114. Auerbach M, Macdougall IC. Safety of intravenous iron formulations: facts and folklore. *Blood transfusion = Trasfusion del sangue*. 2014;12(3):296-300.

115. Rostoker G, Vaziri ND. Risk of iron overload with chronic indiscriminate use of intravenous iron products in ESRD and IBD populations. *Heliyon*. 2019;5(7):e02045.

116. Aldwairi MM, Yassin MA. Iatrogenic iron overload in an end stage renal disease patient. *Case Rep Oncol*. 2020;13(2):760-763.

117. Nuhu F, Seymour A-M, Bhandari S. Impact of intravenous iron on oxidative stress and mitochondrial function in experimental chronic kidney disease. *Antioxidants (Basel, Switzerland)*. 2019;8(10):498.

118. Bhandari S, Pereira DIA, Chappell HF, Drakesmith H. Intravenous iron: From basic science to clinical practice. *Pharmaceuticals*. 2018;11(3):82.

119. Rostoker G, Loridon C, Gruenelli M, et al. Liver iron load influences hepatic fat fraction in end-stage renal disease patients on dialysis: A proof of concept study. *EBioMed*. 2019;39:461-471.

120. Cappellini MD, Musallam KM, Taher AT. Iron deficiency anaemia revisited. *J Intern Med*. 2020;287(2):153-170.

121. Auerbach M, Gafter-Gvili A, Macdougall IC. Intravenous iron: A framework for changing the management of iron deficiency. *Hematol Oncol Clin North Am*. 2018;32(2):213-221.

122. Corradini E, Buzzetti E, Pietrangelo A. Genetic iron overload disorders. *Mol Aspects Med*. 2020;75:100896.

123. Hossein Davoodi S, Jamshidi-Naeini Y, Esmaeili S, Sohrabvandi S, Mortazavi AM. The Dual Nature of Iron in Relation to Cancer: A Review. *Int J Cancer Manag*. 2016;9(6):e5494.

124. Parrow NL, Fleming RE, Minnick MF. Sequestration and scavenging of Iron in Infection. *Infect Immun*. 2013;81(10):3503-3514.

125. Zimmermann MB, Chassard C, Rohner F, et al. Altered iron metabolism and impact in cancer biology, metastasis, and immunology. *Front Oncol*. 2020;10:476.

126. Fonseca-Nunes A, Jakob A, Agudo A. Iron and cancer risk—A systematic review and meta-analysis of the epidemiological evidence. *Cancer Epidemiol Biomarkers Prev*. 2014;23(1):12-31.

127. Yuen H-W, Becker W. Iron toxicity. [Updated 2021 Jul 25]. In: StatPearls [Internet]; :StatPearls Publishing. 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK459224/.
130. Dasa F, Abere T. Factors affecting iron absorption and mitigation mechanisms: A review. Int J Agric Sci Food Technol. 2018;4(1):024-030.

131. Manz DH, Blanchette NL, Paul BT, Torti FM, Torti SV. Iron and cancer: recent insights. Ann NY Acad Sci. 2016;1368(1):149-161.

132. Weinberg ED. Iron therapy and cancer. Kidney Internat. 1999;55:S131-S134.

133. Weinberg E. The role of iron in cancer. Eur J Cancer Prev. 1996;5(1):19-36.

134. Torti SV, Manz DH, Paul BT, Blanchette-Farra N, Torti FM. Iron and Cancer. Annu Rev Nutr. 2018;38(1):97-125.

135. Gangaïzzo I, Gordeuk V. Hepatocellular carcinoma and African iron overload. Gut. 1995;37(5):727-730.

136. Mak D, Kramvis A. Epidemiology and aetiology of hepatocellular carcinoma in Sub-Saharan Africa. Hepatoma Res. 2021;7:39.

137. Witte DL, Crosby WH, Edwards CJ, Fairbanks VF, Mitros FA. Hereditary hemochromatosis. Clin Chim Acta. 1996;245(2):139-200.

138. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis amongst asymptomatic Australians. Br J Haematol. 1990;74(2):525-530.

139. Simon M, Le Mignon L, Fauchet R, et al. A study of 609 HLA associations concerning the underlying cause of hemochromatosis-HLA association. American J Human Genet. 1987;41(2):89.

140. Leggett BA, Halliday JW, Brown NN, Bryant S, Powell LW. Prevalence of haemochromatosis amongst asymptomatic Australians. Br J Haematol. 1990;74(4):525-530.

141. Simon M, Le Mignon L, Fauchet R, et al. A study of 609 HLA haplotypes marking for the hemochromatosis gene: (1) mapping of the gene near the HLA-A locus and characters required to define a heterozygous population and (2) hypothesis concerning the underlying cause of hemochromatosis-HLA association. American J Human Genet. 1987;41(2):89.

142. Wang W, Knovich MA, Coffman LG, Torti FM, Torti SV. Serum ferritin: past, present and future. Biochim et Biophys Acta (BBA)-Gen Subjects. 2010;1800(8):760-769.

143. Filali M, Le Jeunne C, Durand E, et al. Juvenile hemochromatosis HJV-related revealed by cardiogenic shock. Blood Cells Mol Dis. 2004;33(2):120-124.

144. Lehmann U, Wingen LU, Brakensiek K, et al. Epigenetic defects of hepatocellular carcinoma are already found in non-neoplastic liver cells from patients with hereditary haemochromatosis. Hum Mol Genet. 2007;16(11):1335-1342.

145. Kim D-H, Kim J-H, Kim E-H, et al. 15-Deoxy-Δ12, 14-prostaglandin J 2 upregulates the expression of heme oxygenase-1 and subsequently matrix metalloproteinase-1 in human breast cancer cells: possible roles of iron and ROS. Carcinogenesis. 2009;30(4):645-654.

146. Fischer J, Goldfarb D, Elango R, Karakochuk C. Is iron supplementation harmful in populations where iron deficiency is not the cause of anemia? Protocol for a 12 week RCT in Cambodia. Curr Develop Nutr. 2020;4(Supplement_2):1737.

147. Rajendran S, Bobby Z, Habeebullah S, Elizabeth JS. Differences in the response to iron supplementation on oxidative stress, inflammation, and hematological parameters in nonanemic and anemic pregnant women. J Matern-Fetal Neo Med. 2020;35:1-7.

148. Okon IS, Coughlan KA, Zhang M, Wang Q, Zou MH. Gefitinib-mediated reactive oxygen specie (ROS) instigates mitochondrial dysfunction and drug resistance in lung cancer cells. J Biol Chem. 2015;290(14):9101-9110.

149. Luanpitpong S, Talbott SJ, Rojanasakul Y, et al. Regulation of lung cancer cell migration and invasion by reactive oxygen species and caveolin-1. J Biol Chem. 2010;285(50):38832-38840.

150. Chen Y, Ohara T, Xing B, Qi J, Noma K, Matsukawa A. A promising new anti-cancer strategy: Iron chelators targeting CSCs. Acta Med Okayama. 2020;74(1):1-6.

151. Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;11(1):64.

152. Serrano-Gomez SJ, Maziveyi M, Alahari SK. Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer. 2016;15(1):18.

153. Hu L, Hittelman W, Lu T, et al. NGAL decreases E-cadherin-mediated cell–cell adhesion and increases cell motility and invasion through Rac1 in colon carcinoma cells. Lab Invest. 2009;89(5):531-548.

154. Sher AF, Wu S. Effect of bevacizumab on the risk of chemotherapy-associated anemia in cancer patients: A meta-analysis. J Clin Oncol. 2010;28(15_suppl):9136.

155. Rasel M, Mahboobi SK. Transfusion Iron Overload. [Updated 2021 Sep 9]. In: StatPearls [Internet]. StatPearls Publishing; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK562146/

156. Khodaverdian V, Tapadar S, MacDonald IA, et al. Deferiprone: pan-selective histone lysine demethylase inhibition activity and structure-activity relationship study. Sci Rep. 2019;9(1):1-17.

157. Saha MN, Jiang H, Yang Y, Reece D, Chang H. PRIMA-1MET/ APR-246 displays high antitumor activity in multiple myeloma by induction of p73 and Noxa. Mol Cancer Therap. 2013;12(11):2331-2341.

158. Lang J, Zhao X, Wang X, et al. Targeted co-delivery of the iron chelator deferoxamine and a HIF1α inhibitor impairs pancreatic tumor growth. ACS Nano. 2019;13(2):2176-2189.

How to cite this article: Basak T, Kanwar RK. Iron imbalance in cancer: Intersection of deficiency and overload. Cancer Med. 2022;11(20):3837-3853. doi: 10.1002/cam4.4761